Home Tags ASCO

Tag: ASCO

ASCO 2024: A More Effective Treatment Combination for Hodgkin Lymphoma

ASCO 2024: A More Effective Treatment Combination for Hodgkin Lymphoma
Photo: AbbVie R&D has focused on developing biologics. In particular, antibody therapeutics have been proven to be clinically effective for disease areas such as oncology and immunology. Photo courtesy: © 2019 - 2020 AbbVie

ASCO 2024: AbbVie to Showcases Robust Solid Tumor Pipeline with New...

New data from AbbVie's innovative antibody-drug conjugate (ADC) platform will be showcased across three oral presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (May 31 - June 4, 2024).
Astellas Pharma. Exhibition booth during the 2019 annual meeting of the American Society of Medical Oncology (ASCO).

ASCO 2024: Astellas to Showcase Scientific Advancements

During the upcoming 2024 annual meeting of the American Society of Clinical Oncology (ASCO) Annual Meeting, been held from May 31st - June 4th, Astellas...

ASCO’s Call-to Action: Advancing Patient-focused and Decentralized Clinical Trials

Required adaptations to clinical trial design and execution, implemented during the COVID-19 pandemic, have put a new focus on the development of patient-focused, decentralized...

Mirvetuximab Soravtansine Improves Survival in Women With Recurrent Ovarian Cancer

The MIRASOL study (ClinicalTrials.gov identifier: NCT04209855), an international phase 3 randomized clinical trial, found that mirvetuximab soravtansine (Elahere™, ImmunoGen), an antibody-drug conjugate (ADC) and microtubule inhibitor, significantly improved progression-free and overall survival for women with platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha (FRɑ) expression.

Compared to Brentuximab Vedotin, Nivolumab Reduces Risk of Disease Progression in...

Compared to Brentuximab Vedotin, Nivolumab Reduces Risk of Disease Progression in Untreated Hodgkin Lymphoma

What to Expect at ASCO ’23: Mythic Therapeutics’ MYTX-011 Trial In...

During the annual meeting of the American Society of Clinical Oncology (ASCO) held June 2-6, 2023 in Chicago, Illinois, and online, cancer researchers and...

Trastuzumab deruxtecan Doubles Progression-Free Survival in Metastatic Breast Cancer with Low...

The use of trastuzumab deruxtecan (Enhertu®; Daiichi Sankyo and AstraZeneca), a new HER2-targeting antibody-drug conjugate, doubled progression-free survival (PFS) compared to standard-of-care treatment with...

ASCO 2022: Belantamab Mafodotin in the Treatment of Patients with Relapsed/Refractory...

The treatment patients diagnosed with relapsed or relapsed/refractory multiple myeloma (RRMM), those who have relapsed or who are refractory to at least 1 line of...

Sacituzumab Govitecan Increases PFS for Patients With Most Common Type of...

Treatment with sacituzumab govitecan (Trodelvy®; Gilead Sciences), an antibody-drug conjugate (ADC), resulted in longer progression-free survival (PFS) compared to physician’s choice of chemotherapy in...

X